Mulpleta FDA nod in hand, Shionogi must distinguish it from competitor Dova's similar drug
admin 1st August 2018 Uncategorised 0Shionogi has won an FDA nod for Mulpleta, which is designed to boost platelet count in chronic liver disease patients before surgery. The approval comes just two months after Dova’s rival treatment Doptelet became the first drug approved in the U.S. for the condition; and as analysts see it, the competition will be fierce.
More: Mulpleta FDA nod in hand, Shionogi must distinguish it from competitor Dova's similar drug
Source: fierce